Investor Relations
Investor Relations
Print Print     Email Email

Investor Relations

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. Cethrin®, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia. The Company's lead molecular imaging product candidate is Altropane® which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Stock Quote
09/03/10 - 11:09 AM ET
ALSE OT  
Price: $0.23  
Change: + 0.05   
Quotes delayed at least 20 minutes.
Information provided by eSignal.
Featured Reports
Quarterly Report PDF 493.0 KB Add to Briefcase
2008 Proxy Statement PDF 355.0 KB Add to Briefcase
Add to Briefcase = add file to Briefcase


Recent News
RSS News Feeds RSS News Feeds

May 7, 2009
Alseres Shares Begin Trading on the Pink Sheets OTC Market

Apr 30, 2009
Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology

View all releases »

Events & Presentations

View all events & presentations »